enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Cash burn of $3.8 million in Q2 remains in line with projected quarterly range – Cash and investments are sufficient to fund operations through Q3’2026 at current cash burn rate – Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H’2025 – IDE submission for enVVe® on […]